Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 12/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24067461 | 0.86 | CNR1 (0.50) | CNR1DPP4DPP7KCNH2DPP9 | |
| SCHEMBL24182186 | 0.84 | DPP9 (0.43) | CNR1DPP4DPP7KCNH2DPP9 | |
| SCHEMBL22450746 | 0.84 | CNR1 (0.41) | CNR1DPP4DPP7KCNH2DPP9 | |
| SCHEMBL24067467 | 0.84 | CNR1 (0.40) | CNR1EPHX2HTR3ATNF | |
| SCHEMBL24067306 | 0.84 | TNF (0.52) | TNF | |
| SCHEMBL24067344 | 0.84 | TNF (0.52) | TNF | |
| SCHEMBL24067468 | 0.80 | IL1B (0.47) | CNR1 | |
| SCHEMBL24067391 | 0.79 | TNF (0.40) | CNR1HTR3ATNF | |
| SCHEMBL22663739 | 0.77 | CNR1 (0.49) | CNR1DPP4DPP7KCNH2DPP9 | |
| SCHEMBL24067396 | 0.75 | KRAS (0.46) | CNR1DPP4DPP7DPP9DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| EP-3936126-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | BIRC5, XIAP, BIRC2 | CNR1 4767/4885DPP4 663/4885DPP7 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.